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Abstract
Rationale: Pulmonary arterial hypertension (PAH) is a life-
shortening condition. The European Society of Cardiology and
European Respiratory Society and the REVEAL (North American
Registry to Evaluate Early and Long-Term PAH Disease
Management) risk score calculator (REVEAL2.0) identify thresholds
to predict 1-year mortality.
Objectives: This study evaluates whether cardiac magnetic
resonance imaging (MRI) thresholds can be identified and used
to aid risk stratification and facilitate decision-making.
Methods: Consecutive patients with PAH (n= 438) undergoing
cardiac MRI were identified from the ASPIRE (Assessing the
Spectrum of Pulmonary Hypertension Identified at a Referral
Center) MRI database. Thresholds were identified from a discovery
cohort and evaluated in a test cohort.
Measurements and Main Results: A percentage-predicted right
ventricular end-systolic volume index threshold of 227% or a left
ventricular end-diastolic volume index of 58 ml/m2 identified
patients at low (,5%) and high (.10%) risk of 1-year mortality.
These metrics respectively identified 63% and 34% of patients
as low risk. Right ventricular ejection fraction.54%, 37–54%,
and,37% identified 21%, 43%, and 36% of patients at low,
intermediate, and high risk, respectively, of 1-year mortality.
At follow-up cardiac MRI, patients who improved to or were
maintained in a low-risk group had a 1-year mortality,5%.
Percentage-predicted right ventricular end-systolic volume index
independently predicted outcome and, when used in conjunction
with the REVEAL 2.0 risk score calculator or a modified French
Pulmonary Hypertension Registry approach, improved risk
stratification for 1-year mortality.
Conclusions: Cardiac MRI can be used to risk stratify patients with
PAH using a threshold approach. Percentage-predicted right
ventricular end-systolic volume index can identify a high percentage
of patients at low-risk of 1-year mortality and, when used in
conjunction with current risk stratification approaches, can improve
risk stratification. This study supports further evaluation of cardiac
MRI in risk stratification in PAH.
Keywords: risk stratification; pulmonary arterial hypertension;
imaging; disease severity; prognosis
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Pulmonary arterial hypertension (PAH) is a
rare and life-shortening condition (1).
Without treatment, life expectancy is less
than 3 years (2), but with therapy, 5-year
survival exceeds 60% in patients with
idiopathic PAH (3–5). Current licensed
therapies directed at the pulmonary
vasculature target three pathways (6). There
is evidence of superiority of upfront dual
(7) or sequential oral combination therapy
(8, 9) over oral monotherapy, but decisions
regarding escalation to more intensive
treatments, as well as transplantation, can
be challenging.
The European Society of Cardiology
and European Respiratory Society
(ESC/ERS) guidelines propose a “traffic
light” risk-stratification score to aid
physicians in treatment decisions,
categorizing patients as having low risk
(“green,” ,5%), intermediate risk
(“amber,” 5–10%), or high risk (“red,”
.10%) of mortality at 1 year based on a
number of modifiable variables (10). These
include an assessment of symptoms,
exercise capacity, and right ventricular
function (10, 11). Although the thresholds
used for these variables were largely based
on expert opinion, they have since been
validated for PAH in three European
registries (11–13). These studies
demonstrated that patients who improved
to a low-risk profile at follow-up had better
outcomes than those who did not improve.
Outcomes for patients remaining in the
intermediate-risk group were significantly
worse than those for low-risk patients, and
current approaches aim to improve and
maintain patients in the low-risk group
(10, 14). Similar results were observed in
the REVEAL (North American Registry to
Evaluate Early and Long-Term PAH
Disease Management) risk score (15). Risk-
stratification approaches typically include
multiple variables (10, 11); however, right
ventricular function is thought to be the
primary determinant of morbidity and
mortality in PAH (16, 17). Cardiac
magnetic resonance imaging (MRI) is the
recognized gold standard for assessment
of right ventricular function (18–20).
Although echocardiography is more widely
available, cheaper, and the most commonly
used imaging modality for right ventricular
assessment, it is limited by lack of inter-
and intraobserver reproducibility (21) and
acoustic windows (20, 22, 23).
Whereas studies have demonstrated the
prognostic value of cardiac MRI in PAH
(17, 24–27), cardiac changes evaluated by
current risk-stratification tools are limited
to atrial and pericardial assessment. Cardiac
MRI metrics, which are known to be
prognostic in PAH, are not included in
either the REVEAL 2.0 or ESC/ERS risk
scores (10, 28). We sought to identify
whether cardiac MRI metrics could
accurately risk stratify patients using the
ESC/ERS criteria of three levels of risk and
whether thresholds could be used to aid risk
stratification. Some results of this study
were reported previously in the form of an
abstract (29).
Methods
Patients with PAH were identified from the
ASPIRE (Assessing the Spectrum of
Pulmonary Hypertension Identified at a
Referral Center) cardiac MRI database
between April 2012 and March 2017.
Patients underwent systematic evaluation
(30, 31), including echocardiography, blood
testing, exercise testing, lung function
testing, multimodality imaging, and right
heart catheterization. Patients were
required to have mean pulmonary artery
pressure >25 mm Hg and to have had
pulmonary arterial wedge pressure
recorded and were excluded if pulmonary
arterial wedge pressure was .15 mm Hg.
Patients with coexisting lung disease or left
heart disease were excluded. Patients were
listed in date order of cardiac MRI scan and
assigned in alternate date order to the
discovery or test cohort.
MRI Acquisition and Analysis
Cardiac cine MRI was performed on a 1.5-T
GE HDx MRI scanner using an eight-
channel receiver array and multislice
balanced steady-state imaging with
retrospective gating (20 frames per cardiac
cycle; slice thickness, 8 mm; field of view,
48 cm; matrix, 2563 256; bandwidth, 125
kHz/pixel; repetition time/echo time,
3.7/1.6 ms). A stack of images in the short-
axis plane with slice thickness of 8 mm
(2-mm interslice distance) was acquired
covering both ventricles from base to apex.
End systole was considered to be the
smallest cavity area. End diastole was
defined as the first cine phase of the
R-wave–triggered acquisition or largest
volume.
Image analysis was performed by
operators blinded to diagnosis and cardiac
catheter result. Endocardial and epicardial
surfaces were manually traced on short-axis
imaging to obtain end-systolic and end-
diastolic volumes for the right and left
ventricles. Trabeculations for the chambers
were not separately traced and were
included as part of the volume cavity
measurement (32). Right ventricular
ejection fraction (RVEF) was calculated
from these volume measurements as
described previously (33). Volumes were
indexed for body surface area and then
corrected for age and sex and displayed
as percentage predicted, as described
previously (34). Ventricular mass index was
calculated as right ventricular mass divided
by left ventricular mass (35). Pulmonary
artery relative area change was measured
on the magnitude images of phase contrast
images and calculated as the difference of
maximum pulmonary arterial area minus
minimal pulmonary arterial area, divided
by minimal pulmonary arterial area. Phase
contrast imaging parameters were as
follows: repetition time/echo time, 5.6/2.7
ms; slice thickness, 10 mm; field of view, 48
cm, bandwidth, 62.5 kHz; matrix, 256 3128;
40 reconstructed cardiac phases; and
velocity encoding of flow, 150 cm/s.
Patients were in the supine position with a
surface coil and with retrospective ECG
gating.
At a Glance Commentary
Scientific Knowledge on the
Subject: Cardiac magnetic resonance
imaging (MRI) is the gold standard test
to assess right ventricular function and
has a prognostic role in pulmonary
arterial hypertension.
What This Study Adds to the Field:
Improvement and maintenance of a
low-risk profile (,5% mortality at
1 yr) is the current goal of treatment
strategies in patients with pulmonary
arterial hypertension. We identified
and tested cardiac MRI thresholds to
risk stratify patients at baseline and
follow-up. Cardiac MRI can identify a
high percentage of patients at low-risk
of 1-year mortality when used as a sole
risk-stratification tool and can
improve risk stratification when used
in conjunction with current risk-
stratification approaches.
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Statistical Analysis
Statistical analysis was performed using IBM
SPSS version 25 and R software. In this
article, a quintile refers to values that divide
a ranked population into five equal groups.
A quintile group refers to the population
defined by the quintile. Data for continuous
variables are presented as mean6 SD, and
categorical data are presented as absolute
values. Once thresholds were derived,
volumes and values expressed as percentage
predicted were rounded to the nearest
whole integer. Patients who had undergone
lung transplantation were censored at the
time of surgery; all other surviving patients
were censored on February 28, 2019.
Survival curves were assessed using the
log-rank test.
Discovery Cohort
In the discovery cohort, cardiac MRI
parameters were assessed for significance for
1-year mortality using univariate Cox
regression analysis. A P value of ,0.05 was
considered statistically significant. Metrics
significant at univariate analysis were used
to identify thresholds. To identify
thresholds, continuous variables were
categorized into quintile groups for each
metric. The quintiles were used as
inclusive thresholds and were taken to
two decimal places unless further
precision was required. In each quintile
group, 1-year percentage mortality was
calculated. Contiguous quintile groups
sharing the same level of 1-year
mortality (,5%, 5–10%, and .10%)
were combined.
Test Cohort
The derived thresholds were applied to
the test cohort. For each metric, if the
corresponding group did not have the
same level of risk, no further analysis
was undertaken (ie, only those variables
that showed consistency of risk were
retained).
Whole Cohort
Univariate and multivariate analyses of
demographics, hemodynamics, and MRI
parameters were performed using Cox
regression analysis. Locally estimated
scatterplot smoothing regression analysis
was performed on the whole cohort for
percentage mortality at 1 year for MRI
metrics in which consistency of risk was
identified.
Follow-up Data
Follow-up data were obtained for patients
who had undergone further cardiac MRI
after a minimum of 3 months and before
March 31, 2017.
Combination with Other
Risk-Stratification Tools
The REVEAL 2.0 risk score and number of
low-risk criteria by the FPHR (French
Pulmonary Hypertension Registry)
approach were calculated to determine
whether cardiac MRI could further stratify
risk. This was performed in the incident
population, maximizing available data for
each risk score. For the FPHR approach,
the distance threshold of .440 m for the
6-minute walking test was substituted with
a distance threshold of .330 m for a
low-risk incremental shuttle walking test
(36, 37). Receiver operating characteristic
curve analysis was performed to compare
approaches to risk stratification.
Mortality Data
Mortality data were obtained from the NHS
Personal Demographics Service, for which
electronic records are automatically updated
when a death is registered in the United
Kingdom. All patients on PAH therapies
were followed up at our center as part of the
national service specification for patients
with pulmonary hypertension. No patients
were lost to follow-up.
Ethics approval was granted by the
local ethics committee (STH14169;
“Assessing outcomes in patients with
PAH using cardiac MRI,” ASPIRE Study
004).
Results
Between April 2012 and March 2017,
2,008 patients were identified and 438
had PAH and met inclusion criteria
(Figure 1). Demographic data are
displayed in Table 1. At the time of
cardiac MRI, 51% of patients were
incident and treatment naı̈ve and 49%
were prevalent. The mean age was 56.6
years, and 75% were female. The
majority (85%) had idiopathic PAH,
heritable PAH, or PAH in association
with connective tissue disease.
Portopulmonary hypertension and PAH
in association with congenital heart
disease composed 14% of patients. The
remainder had PAH related to
HIV infection or induced by drugs and
toxins.
During the course of the study, 72%
of patients received combination therapy
(Table 1). A small number of patients,
including nitric oxide vasoresponders
maintained on calcium channel blockers,
did not receive targeted treatment.
Discovery and test cohorts were well
matched, and confidence intervals (CIs)
included the value zero for all continuous
variables including cardiac MRI metrics
(Tables 1 and 2).
Survival Analysis
At 1 year after cardiac MRI, 38 patients
(8.7%) had died; 20 patients (9.1%) were in
the discovery cohort and 18 patients (8.2%)
were in the test cohort. Patients older than
50 years were more likely to die at 1 year
(P= 0.008), as were those with PAH
associated with connective tissue disease
(P= 0.001). Univariate and multivariate
analyses for the whole cohort are shown
in Table E1 in the online supplement.
Results of Cox regression analysis for
cardiac MRI variables in the discovery
cohort, based on survival at 1 year, are
shown in Table 3.
Discovery and Test Cohorts
Quintile groups for each cardiac metric in
the discovery group are displayed in Table
E2. Calculated 1-year mortality per quintile
group is presented in graphical form
(Figure 2).
Derived thresholds were applied to
the test cohort (Table E3). Levels of risk
were nonconcordant between the discovery
and test cohorts for right ventricular
end-systolic volume index (RVESVi),
percentage-predicted right ventricular
end-diastolic volume index, percentage-
predicted RVEF, and percentage-predicted
left ventricular end-diastolic volume index
(LVEDVi) and were excluded from further
analysis.
Three variables were concordant for
levels of risk. Using a threshold of
percentage-predicted RVESVi of 227%,
patients could be stratified into a low-risk
group (1-yr mortality, 4.3%), and a high-risk
group (1-yr mortality, 15%). The low-risk
group (those with percentage-predicted
RVESVi below this threshold) represented
63% of the test cohort (56% of incident
patients and 72% of prevalent patients)
(Figure 3). Left ventricular end-diastolic
volume index stratified patients into a
ORIGINAL ARTICLE
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low-risk group (1-yr mortality, 2.7%),
and high-risk group (1-yr mortality, 11%)
using a threshold of 58 ml/m2. The
low-risk group (those with an LVEDVi
above this threshold) represented 34%
of the test cohort (26% of incident
patients and 43% of prevalent patients).
RVEF stratified patients into low
(1-yr mortality, 4.4%)-, intermediate
(7.4%)-, and high (11.4%)-risk groups
using thresholds of .54%, 37–54%, and
,37%, respectively. Using RVEF, 21% of the
test cohort was identified as low risk, 43% as
intermediate risk, and 36% as high risk.
When the analysis was repeated and
patients with congenital heart disease were
excluded, thresholds for RVEF and LVEDVi
were unchanged. The threshold for
percentage-predicted RVESVi changed
from 227% to 225%.
There was no evidence of significant
collinearity among LVEDVi, percentage-
predicted RVESVi, and RVEF.
Follow-up Data
Follow-up cardiac MRI was performed
in 165 patients. At follow-up,
MRI Database
2,008 patients
RHC performed
mPAP 25mmHg
438 patients1,570 patients
1,331 patients 239 patients
PAWP 15mmHg
920 patients 411 patients
Groups 3, 4, and 5
excluded
438 patients
included in study
482 patients
Yes No
Yes No
Yes
Discovery group
219 patients
Test group
219 patients
18 deaths at 1 year20 deaths at 1 year
No PAWP recorded/
PAWP >15mmHg 
Figure 1. Flowchart showing patients included and reasons for exclusion. mPAP=mean pulmonary artery pressure; MRI =magnetic resonance imaging;
PAWP=pulmonary arterial wedge pressure; RHC= right heart catheterization.
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percentage-predicted RVESVi and RVEF
were able to risk stratify patients based
on thresholds identified in the discovery
cohort. Using percentage-predicted
RVESVi for those who remained low risk
(percentage-predicted RVESVi ,227%)
or improved to low risk (67% of patients
in total), 1-year survival was 96.3%,
whereas for those who remained high
risk or deteriorated to high risk (33% of
patients in total), 1-year survival was
87.3% (Figure 4). RVEF was able to
stratify patients into high and low risk of
1-year mortality at follow-up. Patients
with RVEF ,37% (25% of patients) had
1-year survival of 83.3%, whereas
patients with RVEF of 37% to 54% (45% of
patients) and .54% (29% patients) had 1-
year survival of 97.3% and 95.8%,
respectively.
Combining Cardiac MRI with REVEAL
and FPHR Scores
The REVEAL 2.0 and modified FPHR
scores, in isolation and in combination with
percentage-predicted RVESVi, are displayed
for the incident population (n= 224) in
Figure 5. For REVEAL 2.0, all patients had
at least 11 of the 13 parameters available,
and for modified FPHR, no data were
missing. In those with a REVEAL 2.0 score
>8 and in those determined to be either
intermediate or high risk by the modified
FPHR approach, percentage-predicted
RVESVi reclassified patients into higher or
lower risk categories (Figure 5).
Based on REVEAL 2.0 risk scores <6
for low risk, 7 to 8 for intermediate risk,
and >9 for high risk (28) and using a
dichotomized score of 12 or 22 for the
percentage-predicted RVESVi threshold of
227%, MRI reclassified 47% of patients:
36% (n= 82) into a lower risk group and
11% (n= 25) into a higher risk group.
Receiver operating characteristic curves
are displayed in Figure 6. For the
REVEAL 2.0 risk score, addition and
subtraction of 2 points for a percentage-
predicted RVESVi >227% and ,227%,
respectively, increased the C statistic from
0.74 (95% CI, 0.65–0.83) to 0.78 (95% CI,
0.70–0.87). Using the modified FPHR
approach, the C statistic increased from
0.70 (95% CI, 0.59–0.80) to 0.74 (95% CI,
0.63–0.84) by adding an additional point
for patients with a percentage-predicted
RVESVi ,227%.
Verification of Thresholds
For LVEDVi, percentage-predicted
RVESVi, and RVEF, locally estimated
Table 1. Baseline Demographics
All Patients (n=438) Discovery (n= 219) Test (n= 219)
Demographics
Age, yr 56.6615.9 56.06 15.7 57.2616.1
Sex, F/M (F %) 327/111 (75) 161/58 (74) 166/53 (76)
WHO FC I, n (%) 7 (2) 4 (2) 3 (1)
WHO FC II, n (%) 118 (27) 59 (27) 59 (27)
WHO FC III, n (%) 261 (60) 128 (58) 133 (61)
WHO FC IV, n (%) 52 (12) 28 (13) 24 (11)
Incident/prevalent (I%) 225/213 (51) 109/110 (50) 116/103 (53)
ISWD, m 2316194 2376 196 2236193
PAH subtype, n (%)
IPAH/HPAH 197 (45) 101 (46) 96 (44)
PAH-CTD 163 (37) 78 (36) 85 (39)
PAH-CHD 38 (9) 18 (8) 20 (9)
PoPH 25 (6) 16 (7) 9 (4)
Other 15 (3) 6 (3) 9 (4)
Maximal treatment, n (%)
None targeted 23 (5) 12 (6) 11 (5)
Oral monotherapy 100 (23) 46 (21) 54 (25)
Oral combination 205 (47) 101 (46) 104 (47)
Prostanoid with or without oral 110 (25) 60 (27) 50 (23)
Hemodynamics*
mRAP, mm Hg 106 5 1065 1065
mPAP, mm Hg 48614 476 14 48615
PAWP, mm Hg 116 3 1163 1163
Cardiac output, L/min 5.061.8 5.16 1.8 4.961.8
Cardiac index, L/min/m2 2.861.0 2.86 1.0 2.761.0
PVR, dyn $ s $ cm25 7116447 6886 432 7356462
SvO2, % 65.4610.1 66.369.9 64.5610.3
Survival analysis
Deceased at 1 yr after cardiac MRI, n (%) 38 (8) 20 (9) 18 (8)
Definition of abbreviations: HPAH=heritable pulmonary arterial hypertension; IPAH= idiopathic pulmonary arterial hypertension; ISWD= incremental
shuttle walking test distance; mPAP=mean pulmonary arterial pressure; mRAP=mean right atrial pressure; MRI =magnetic resonance imaging;
PAH=pulmonary arterial hypertension; PAH-CHD=PAH associated with congenital heart disease; PAH-CTD=PAH associated with connective tissue
disease; PAWP=pulmonary arterial wedge pressure; PoPH=portopulmonary hypertension; PVR=pulmonary vascular resistance; SvO2=mixed venous
oxygen saturation; WHO FC=World Health Organization functional class.
Data are shown as mean6SD unless otherwise indicated. For all continuous variables, the difference between 95% confidence intervals for the groups
included the value zero.
*Measured at right heart catheterization.
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scatterplot smoothing regression analysis
confirmed that identified thresholds were
within the CIs for the associated risk of
1-year mortality (Figure E1).
Discussion
To our knowledge, this study is the first to
identify cardiac MRI thresholds that can be
used to risk stratify patients with PAH
according to the ESC/ERS “traffic light”
approach at baseline and follow-up.
Furthermore, the addition of percentage-
predicted RVESVi independently predicted
outcome and, when used in conjunction
with current approaches, improved risk
stratification.
A number of studies have
demonstrated the prognostic value of
cardiac MRI in PAH at baseline and
follow-up (17, 24–27, 38). In addition
to volumetric measurements, RVEF, right
ventricular to pulmonary artery coupling
metrics and pulmonary artery relative
area change (17, 39–41) have also been
shown to be prognostic. In this study, we
confirmed the prognostic value of cardiac
MRI, but, specifically, we identified and
tested thresholds that may improve its
clinical utility by allowing incorporation
into risk stratification scores, which are
increasingly used to inform treatment
decisions (42).
RVEF is the most commonly reported
cardiac MRI metric, and this study confirms
its prognostic value but also identifies
thresholds that can be used to identify
patients at low risk (RVEF .54%),
intermediate risk (RVEF 37–54%), and high
risk (RVEF ,37%) of 1-year mortality. The
threshold of RVEF ,35% in a previous
study of 76 incident patients with PAH,
identified as conferring a higher risk of
mortality over a median follow-up period of
59 months (17), is similar to that identified
in our study of ,37% for high-risk patients.
Using the ESC/ERS approach to risk
stratification, 21%, 43%, and 36% of patients
were identified at low, intermediate, and
high risk of 1-year mortality, respectively, in
the test cohort, similar to the results of
approaches using multiple noninvasive and
invasive parameters to assess risk (12, 13).
Thresholds identified from this study for
RVEF could be incorporated into the
ESC/ERS risk stratification table to aid
decision making.
In this study, baseline volumetric
measurements of percentage-predicted
RVESVi and LVEDVi were both prognostic.
We previously demonstrated in a large study
of 576 patients with PAH that percentage-
predicted RVESVi was the cardiac MRI
measurement with the strongest prognostic
value (33), and in this study also
independently predicted outcome.
Table 2. Cardiac Magnetic Resonance Imaging Metrics
Metric All Patients (n=438) Discovery (n= 219) Test (n=219)
Right-sided measurements
RVESVi, ml/m2 53.06 27.0 54.5626.9 51.56 27.1
RVEDVi, ml/m2 88.66 33.5 89.9633.7 87.36 33.7
RVESVi %pred 220.06 117.7 225.66122.7 214.46 112.5
RVEDVi %pred 120.46 45.3 121.9646.7 118.96 44.0
RVEF, % 42.06 13.3 41.0613.6 43.06 13.0
RVEF %pred 62.76 20.1 61.4620.7 64.06 19.4
Left-sided measurements
LVESVi, ml/m2 17.36 8.2 17.969.1 16.76 7.1
LVEDVi, ml/m2 54.06 16.1 54.6617.0 53.46 15.1
LVESVi %pred 71.86 33.8 74.1638.3 69.66 28.4
LVEDVi %pred 73.06 21.5 73.5622.8 72.56 20.2
LVEF, % 68.36 10.0 67.7610.6 68.96 9.4
LVEF %pred 100.96 14.7 100.2615.7 101.76 13.7
Miscellaneous
VMI 0.5296 0.297 0.52860.296 0.5316 0.299
PA relative area change, % 11.996 8.70 12.3969.20 11.576 8.15
Definition of abbreviations: %pred=percentage predicted for age and sex; LVEDVi = left ventricular end-diastolic volume index; LVEF= left ventricular
ejection fraction; LVESVi = left ventricular end-systolic volume index; PA=pulmonary artery; RVEDVi = right ventricular end-diastolic volume index;
RVEF= right ventricular ejection fraction; RVESVi = right ventricular end-systolic volume index; VMI = ventricular mass index.
Data are shown as mean6SD. For all variables, the difference between 95% confidence intervals for the groups included the value zero.
Table 3. Univariate Analysis in Discovery Cohort
Metric Univariate Hazard Ratio P Value n
RVESVi, ml/m2 1.016 0.022 219
RVEDVi, ml/m2 1.009 0.150 219
RVESVi %pred 1.004 0.002 219
RVEDVi %pred 1.008 0.045 219
RVEF, % 0.955 0.008 219
RVEF %pred 0.966 0.003 219
LVESVi, ml/m2 0.935 0.055 219
LVEDVi, ml/m2 0.936 0.000 219
LVESVi %pred 0.987 0.113 219
LVEDVi %pred 0.957 0.000 219
LVEF, % 0.974 0.142 219
LVEF %pred 0.980 0.085 219
VMI 2.728 0.140 210
PA relative area change, % 0.956 0.121 219
For definition of abbreviations, see Table 2.
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However, it is important to recognize that
right ventricular volumes decrease with
advancing age, are larger in men, and
increase with body surface area (43). Our
group and others have previously identified
the need to adjust cardiac MRI variables for
age, sex, and body surface area (33, 34, 44),
and this study demonstrates for right
ventricular volumes that correction for
these variables is important when risk
stratifying patients. In this study,
pulmonary artery relative area change did
not predict short-term mortality (1 yr),
whereas it did predict mortality during the
duration of this study (P, 0.005). This
highlights that MRI metrics that measure
right ventricular function may be more
helpful in defining short-term mortality.
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Figure 2. Histograms displaying quintile groups and percentage of mortality at 1 year for cardiac magnetic resonance imaging variables (discovery). Blue
dashed lines represent division into categories of risk. *Division into risk categories was not performed. %pred=percentage predicted for age and sex;
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RVESVi = right ventricular end-systolic volume index.
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Although we were able to identify low,
intermediate, and high risk of 1-year
mortality for RVEF, we were able to
identify only patients at low and high-risk
of 1-year mortality using volumetric
measurements of percentage-predicted
RVESVi and LVEDVi. Thresholds for
percentage-predicted RVESVi ,227% and
LVEDVi .58 ml/m2 identified low-risk
patients. An LVEDVi threshold ,40 ml/m2
was previously used to identify patients at
increased risk of mortality (26), but our
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Figure 3. Histograms displaying percentage mortality at 1 year for derived thresholds for cardiac magnetic resonance imaging variables (test cohort).
% pred=percentage predicted for age and sex; LVEDVi = left ventricular end-diastolic volume index; RVEF= right ventricular ejection fraction; RVESVi = right
ventricular end-systolic volume index.
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Figure 4. (A–F) Kaplan–Meier survival curves for RVESVi %pred at baseline (test cohort) (A), RVESVi %pred at follow-up cardiac magnetic resonance
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study suggests that an LV volume of <58
ml/m2 confers a high risk of mortality at
1 year. Using a threshold for percentage-
predicted RVESVi ,227% and for left
ventricular volume of .58 ml/m2, 63%
and 34% of patients, respectively, could
be identified at low risk of 1-year
mortality. RVEF identified 21% and 43%
of patients as low and intermediate risk,
respectively.
Treatment strategies are currently
based on maintaining or improving
patients to a low-risk group, and a
dichotomized score identifying low- and
high-risk groups may be a preferable
approach to informing and simplifying
treatment decisions. In particular, data
from a number of studies have
demonstrated that patients identified as
intermediate risk using current risk
stratification scores have significantly
worse survival than low-risk patients.
Identification and maintenance of a low-
risk status remains the goal of current
treatment strategies. A number of registry
studies have shown that in patients whose
risk profile can be modified to low risk,
outcomes are significantly improved
(13, 15). However, registry analysis using
current approaches to risk stratification
has identified only small numbers of
patients in this low-risk category at
presentation (12% of patients in COMPERA
[Comparative, Prospective Registry of
Newly Initiated Therapies for Pulmonary
Hypertension] [13] and 23% in the Swedish
registry); at follow-up, more patients
achieved low-risk status (24% in COMPERA,
39% in the Swedish registry [12], and 42% in
the French registry [11]). In contrast, in this
study using percentage-predicted RVESVi,
63% of patients overall could be identified as
low risk in the test cohort, with 56% of
incident patients (newly diagnosed) and
72% of prevalent patients (following
initiation of treatment). One-year mortality
of all incident patients in this registry was
10.7% compared with 11.0% in COMPERA
and 14% in the Swedish registry; for
prevalent patients, 1-year mortality was
6.6% in our cohort, 10.3% in COMPERA,
and 9% in the Swedish registry. Whereas
the French registry included idiopathic,
heritable and drug-induced PAH, the
COMPERA, Swedish registry, and our own
registry also included patients with other
forms of PAH, predominantly related to
connective tissue diseases. The hemodynamic
parameters of our patients were similar to
those in COMPERA and the French
registry, although COMPERA includes a
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smaller proportion of patients in World
Health Organization Functional Class II.
The enrollment period in our study is more
recent, and .70% of patients received
combination therapy. Nonetheless, at
diagnosis, cardiac MRI was able to identify
a high percentage of patients at low risk
(56%). Our findings suggest that assessing
right ventricular function using gold
standard techniques may be preferable
to other investigative approaches if
identification of patients at low risk of
1-year mortality is the goal. Further study
is required to test this hypothesis. Using
thresholds identified in the discovery
cohort, we also demonstrated that cardiac
MRI measurements can be used at follow-
up to risk stratify patients and that
improvement to low risk or maintenance of
patients in a low-risk group is strongly
prognostic.
Finally, we assessed how cardiac MRI
could be used in conjunction with current
risk-stratification approaches; percentage-
predicted RVESVi, when used in conjunction
with REVEAL 2.0 and modified FPHR,
was able to further risk stratify patients.
For patients classified as low risk by
the modified FPHR or with a REVEAL 2.0
risk score <6, MRI did not affect risk
stratification. However, when used in
conjunction with the REVEAL 2.0 risk
calculator and using a dichotomized score
of 12 or 22 points for a percentage-
predicted RVESVi threshold of 227%, for
patients with a REVEAL 2.0 score .6, MRI
was able to reclassify 36% of patients into a
lower risk group and 11% of patients into a
higher risk group.
Limitations
Our approach to identifying thresholds for
risk stratification using quintile groups in
the discovery cohort is a valid but empiric
approach. If the sample size were larger,
other cardiac MRI parameters might have
been identified. Like the COMPERA and
Swedish registries, we included patients with
congenital heart disease. Although repeated
analysis with these patients excluded
identified unchanged or similar thresholds,
we recommend further study in congenital
heart disease, and thresholds in this study
should be used with caution in this
population. The aim of this study was to
assess whether a threshold approach could
be used to risk stratify patients using MRI,
and the methodology used may not have
identified optimal thresholds. Our findings
would benefit from external validation.
Conclusions
Thresholds derived from cardiac MRI
metrics may be used to risk stratify
patients with PAH. This registry
demonstrates that cardiac MRI, when
used as a sole risk-stratification tool,
identifies a high percentage of patients at
low risk of 1-year mortality and can
improve risk stratification when used in
conjunction with current risk stratification
approaches. n
Author disclosures are available with the text
of this article at www.atsjournals.org.
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